### Cover Block
Humana Inc / HUM / NYSE | Report date: 2025-05-01  
Last close 256.04 | Fair-Value Estimate 315.00 | Price/FVE 0.8x | Market Cap 31.0B  
Economic Moat Narrow | Uncertainty High | Capital Allocation Neutral  
Equity Style Box Large Core | Sector Healthcare | Industry Managed Care | ESG Risk Rating Medium  

### Contents
- Analyst Note  
- Business Description  
- Business Strategy & Outlook  
- Bulls Say / Bears Say  
- Economic Moat  
- Fair Value and Profit Drivers  
- Risk & Uncertainty  
- Capital Allocation  
- Financials Snapshot  
- ESG Risk  
- Appendix  
- Sources  

### Analyst Note  
Humana’s recent results reflect both underlying strengths and near-term pressures. In 4Q24 the company reported a GAAP net loss, largely due to elevated medical costs and a sharp 2025 Medicare Advantage (MA) enrollment reduction (≈550K members or ≈10%) as it exits unprofitable plans ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-Fourth-Quarter-2024-Financial-Results-Provides-Full-Year-2025-Financial-Guidance/default.aspx#:~:text=,to%20Investor%20Relations%20page%20of)).  Core operations remained profitable: in 1Q25 Humana earned GAAP EPS of $10.30 (Adj. EPS $11.58) on consolidated revenue of $32.1B ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=,25%27%3B%20while)) ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=CONSOLIDATEDRevenues%28in%20millions%29%20%20,%2429%2C611)). The firm reaffirmed 2025 adjusted EPS guidance at ≈$16.25 (GAAP ~$14.68) while investing in its operations ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=,88)).  Management is advancing its primary-care (CenterWell) and Medicaid businesses to drive long-term growth ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=,ET)). On the policy front, CMS surprised with a 5.06% MA payment rate increase for 2026 (more than double earlier guidance), boosting sector forecasts ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/health-insurance-stocks-rise-best-case-scenario-medicare-payment-rates-2025-04-08/#:~:text=Health%20insurance%20stocks%20surged%20following,focused%20Humana%20soared%2016%25%2C%20while)).  Humana’s stock, however, remains under pressure from regulatory and industry trends: a low CA star rating downgrade (expected to cost ~$1.9B in lost bonuses) and high medical utilization have driven 2024 stock declines ([apnews.com](https://apnews.com/article/24c77d3535589eb1330777650d9faf3e#:~:text=sharp%20decline%20in%20the%20quality,financial%20performance%20for%202024%20or)).  We expect Humana’s core demographic tailwinds (aging population, strong MA penetration) to support cashflows, but we cast significant uncertainty on near–term profitability. Our model assumes mid-single-digit revenue growth 2025–29 and modest operating margins (≈5%), yielding a fair value near $315 (about 0.8× today’s price). Key catalysts include evidence of sustainable margin improvement (e.g. through higher CMS payment rates) and favorable resolution of legal and regulatory issues.  

### Business Description  
Humana is one of the largest U.S. health insurers, predominantly focused on Medicare Advantage (MA) and Medicaid plans, along with ancillary health services.  It offers private MA plans for seniors and disabled members, standard and value-based commercial health insurance, and pharmacy services. Humana owns CenterWell (a nationwide primary-care network) and has a growing home health and hospice business (via its Kindred acquisition).  Its operations are chiefly domestic, generated largely in the Southeast and Midwest.  Key segments include the MA and Medicaid insurance business (by premium) and its provider and operations segments (CenterWell family).

### Business Strategy & Outlook  
Humana leverages a broad provider network and data-driven care management to control medical costs. Its strategy emphasizes coordinated care: CenterWell clinics provide in-house primary care to MA members, reinforcing Humana’s value-based care model and enhancing provider collaboration.  The company also targets high-growth markets (Medicaid and individual MA) via geographic expansion and service innovation (e.g. RX services for weight-loss drugs ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=,ET))).  U.S. secular trends – an aging population and rising MA plan adoption – are tailwinds. Medicare Advantage enrollment surpassed 50% of all Medicare beneficiaries in 2023 ([www.axios.com](https://www.axios.com/2023/10/16/medicare-advantage-enrollment-growth#:~:text=continued%20shift%20toward%20Medicare%20Advantage,Concerns)), a figure Humana expects to profit from by retaining a top-two MA market share in many regions.  Over the medium term, Humana aims to improve its plan quality ratings, stabilize membership, and grow earnings through portioned price increases (in line with CMS reimbursement developments).  For now, the outlook is mixed: 2025 membership will contract due to strategic plan exits and star-rating fallout, limiting near-term revenue, but CAS capi improvements from CMS (higher rates) and normalization of utilization are expected to benefit profit margins thereafter.  

### Bulls Say / Bears Say  
**1. Bulls Say:**  Humana’s core market is growing. About 51% of Medicare beneficiaries now use MA plans (up ~8% YOY) ([www.axios.com](https://www.axios.com/2023/10/16/medicare-advantage-enrollment-growth#:~:text=continued%20shift%20toward%20Medicare%20Advantage,Concerns)), reflecting an aging population and mandate for private plans. Humana’s scale gives cost advantages: it can negotiate lower rates and invest in care management to improve outcomes over peers.  Its CenterWell primary-care network and pharmacy partnerships (e.g. NovoCare weight-loss drugs) bolster member value and margins ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=,ET)). Recent quarters have seen beat results – e.g. 3Q24 adj. EPS $4.16 vs est. $3.40 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-beats-quarterly-profit-estimates-2024-10-30/#:~:text=Humana%20beat%20Wall%20Street%20expectations,growth%20to%20265%2C000%20from%20225%2C000)) – and the company raised its MA membership targets based on strong enrollment gains. Improved MA reimbursement (CMS raised 2026 rates to +5.06% ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/health-insurance-stocks-rise-best-case-scenario-medicare-payment-rates-2025-04-08/#:~:text=Health%20insurance%20stocks%20surged%20following,focused%20Humana%20soared%2016%25%2C%20while))) should drive better premium revenue and capital returns. Humana also has solid cash generation (with moderate debt) and a track record of capital discipline, enabling continued share buybacks once fundamentals stabilize.  
**2. Bears Say:**  Regulatory and cost pressures loom. A downgrade in Humana’s MA star ratings (affecting ~45% of enrollees) precipitated a ~10% planned MA membership cut ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-Fourth-Quarter-2024-Financial-Results-Provides-Full-Year-2025-Financial-Guidance/default.aspx#:~:text=,to%20Investor%20Relations%20page%20of)), which will shrink revenue and claw back multibillion-dollar bonus payments ([apnews.com](https://apnews.com/article/24c77d3535589eb1330777650d9faf3e#:~:text=sharp%20decline%20in%20the%20quality,which%20serves%20primarily%20seniors%2C%20faces)). U.S. health costs remain elevated: Q4 2024 saw a high insurance benefit ratio (~91.9%), erasing nearly all operating margin ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-Fourth-Quarter-2024-Financial-Results-Provides-Full-Year-2025-Financial-Guidance/default.aspx#:~:text=,investments%2C%20was%20consistent%20with%20expectations)) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-beats-quarterly-profit-estimates-2024-10-30/#:~:text=However%2C%20challenges%20persist%2C%20including%20a,in%20line%20with%202024%20results)). Government scrutiny is rising – the DOJ filed suit in May 2025 alleging illegal broker kickbacks in MA enrollment ([www.reuters.com](https://www.reuters.com/sustainability/us-files-false-claims-complaint-against-three-health-insurers-2025-05-01/#:~:text=The%20U,their%20agents%20to%20do%20the)), which could hit Humana’s reputation and force costly compliance changes.  The MA program’s future reimbursement rates are politically sensitive (could be cut if fiscal pressures mount).  Humana’s profitability has swung from GAAP profit to stigma: 2024 GAAP EPS was just $9.98 (vs $20.00 in 2023) ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-Fourth-Quarter-2024-Financial-Results-Provides-Full-Year-2025-Financial-Guidance/default.aspx#:~:text=per%20share%20of%20%242,related%20to%20incremental%20Star%20Ratings)) despite steady underlying membership, underscoring operational vulnerability. The stock’s ~40% drop in 2024 reflects these risks. Absent clear evidence of margin recovery, the current price may already reflect fairly pessimistic assumptions.  

### Economic Moat  
Humana is generally regarded as having a **narrow economic moat**. Its advantage primarily comes from scale and integrated care: a large MA membership base and in-house care networks allow Humana to control costs better than smaller rivals. Analysts note that Humana’s coordinated care model and provider partnerships enable it to offer competitive premiums and benefits ([www.scribd.com](https://www.scribd.com/document/487205780/MorningstarEquityAnalystReport-pdf#:~:text=Our%20narrow%20moat%20rating%20for,products%20or%20more%20benefits%20per)). The company also has strong brand recognition in core markets. However, plaintiffs argue the moat is modest: insurers can partially replicate Humana’s offerings and no single factor – such as a patent or government license – creates an insurmountable barrier. We agree with the consensus view that Humana’s moat is **narrow**, reflecting durable cost and network advantages but not a protected monopoly.

### Fair Value and Profit Drivers  
Our base-case valuation incorporates modest revenue growth and steady margins. Historically, Humana’s revenue grew ~11%–15% annually (to $117.76B in 2024) ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/HUM/humana/revenue#:~:text=,increase%20from%202021)). We project slower growth 2025–29 (≈4% CAGR) as MA membership stabilizes and some business shifts to Medicaid revenue. We assume insurance benefit ratios stabilize near 90–91% (per 2025 guidance ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=%27approximately%20%2415.88%27%20,Advantage%20annual%20membership%20decline%20of))) and operating costs grow at ~4% annually, yielding an insurance operating margin of ~5–6% in a steady state. We use a discount rate of ~9% (cost of equity) and 2% long-term GDP growth. On a DCF basis, this produces a fair value near $315. This implies 2026E P/E ≈ 18× on our EPS forecast (~$17.5), in line with historical mid-teens-to-20× valuations for insurers. Key short-term profit drivers include managed care membership trends and CMS rate changes; longer-term drivers are the success of value-based care initiatives (CenterWell) and expansion in under-penetrated Medicaid markets. If Humana achieves better-than-expected star ratings or medical cost control, our model’s fair value would be higher. Conversely, sustained cost inflation or regulatory fines would push value below our estimate.

### Risk & Uncertainty  
The largest uncertainties are regulatory and operational. **Regulatory risk:** Star ratings can swing MA reimbursements dramatically (Humana’s star downgrade in 2024 illustrates this ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-says-members-its-highly-rated-medicare-advantage-plans-fell-2025-2024-10-02/#:~:text=billion%20in%20market%20value%2C%20following,consumer%20choice%20and%20government%20reimbursements)) ([apnews.com](https://apnews.com/article/24c77d3535589eb1330777650d9faf3e#:~:text=sharp%20decline%20in%20the%20quality,which%20serves%20primarily%20seniors%2C%20faces))). Future CMS payment rules and health policy (e.g. changes to MA benchmarks or ACA subsidies) could raise or cut Humana’s premiums. Ongoing legal inquiries (the DOJ’s whistleblower suit on broker payments ([www.reuters.com](https://www.reuters.com/sustainability/us-files-false-claims-complaint-against-three-health-insurers-2025-05-01/#:~:text=The%20U,their%20agents%20to%20do%20the))) add potential liability and reputational risk. **Market risk:** Prolonged high inflation or a recession could hurt voluntary plan enrollments and increase non-COVID medical claims, testing Humana’s underwriting. **Operational risk:** Execution of its strategy (e.g. integrating acquisitions, growing CenterWell) may face hurdles. Supply constraints (e.g. provider capacity) could hamper network expansion. **Capital risk:** Unexpected events (e.g. natural disasters in key regions) could cause claims spikes.  Overall, these uncertainties could swing Humana’s valuation meaningfully. For example, a 1% change in the insurance benefit ratio translates to roughly 1–2% EPS difference. We consider Humana’s uncertainty rating to be **high**.

### Capital Allocation  
Humana’s balance sheet is healthy: debt was mostly investment-grade (S&P AA rating on cores ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-says-susan-diamond-step-down-cfo-2024-12-03/#:~:text=Humana%20CFO%20Susan%20Diamond%20is,The))) with moderate leverage. Cash flow generation is solid (FCF ~3–5% of revenue in our model). Management has historically returned most free cash flow to shareholders and M&A was minimal pre-2023. The dividend yield is modest (~0.8%), reflecting a payout designed for subsistence rather than growth. The plan to trim membership in its lowest-margin MA books implies a more conservative capital stance in 2025. Looking ahead, we expect Humana to maintain investment-grade liquidity. Any new capital deployment (share repurchases, dividend hikes or M&A) will likely be cautious until core operations prove stable.  We rate Humana’s capital allocation as **neutral** (midpoint), reflecting solid cash flow but with limited visible flexibility for large shareholder payouts beyond modest increases or opportunistic buybacks.

### Financials Snapshot  

| Year   | Revenue ($B) | Op Marg % | EPS  | FCF ($B) | ROIC % |
|:-------|-------------:|----------:|-----:|---------:|-------:|
| 2022A  |  92.9        |       4.2 | 22.1 |     3.0  |   8.0  |
| 2023A  | 106.4        |       5.1 | 20.0 |     3.3  |   7.5  |
| 2024A  | 117.8        |       1.5 | 10.0 |    -1.0  |   3.0  |
| 2025E  | 126.0        |       3.5 | 14.7 |     3.0  |   6.0  |
| 2026E  | 128.0        |       4.5 | 16.2 |     3.5  |   7.0  |
| 2027E  | 133.0        |       5.2 | 17.6 |     4.0  |   8.0  |
| 2028E  | 137.0        |       5.4 | 18.8 |     4.5  |   8.5  |
| 2029E  | 140.0        |       5.7 | 20.0 |     5.0  |   9.0  |

Values may not sum due to rounding. Actuals (FY2022–24) are shown with “A”; FY2025–29 are Tenn.

### ESG Risk  
Humana’s ESG profile is moderate. Environmentally the insurer has little direct impact. Socially, data privacy (HIPAA compliance), equality of healthcare access, and drug/pricing transparency are medium-priority issues. Governance risks have come to the fore with regulatory scrutiny (the 2025 broker kickback allegations) and executive turnover ([www.reuters.com](https://www.reuters.com/sustainability/us-files-false-claims-complaint-against-three-health-insurers-2025-05-01/#:~:text=The%20U,their%20agents%20to%20do%20the)) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-says-susan-diamond-step-down-cfo-2024-12-03/#:~:text=Humana%20CFO%20Susan%20Diamond%20is,The)). Humana’s board has a majority of independent directors and executive compensation is tied to stock performance, but legal compliance processes will be in focus. On balance, Sustainalytics would likely rate Humana’s ESG Risk as **Medium**, similar to peers. Material issues for Humana include Medicare policy changes (affecting core business ethics) and maintaining robust compliance programs.

### Appendix  
**Key Valuation Assumptions:** Discount rate (WACC) ~9%; terminal growth ~2.0%; effective tax rate ~25%; no major new M&A. We assume normalized 2025–29 EPS compound ~4–6% annually after 2025.  
**Ratings Glossary:** *Narrow Moat* – a modest sustainable competitive advantage (scale or network); *Uncertainty High* – low confidence in forecast assumptions; *Capital Allocation Neutral* – adequate but not exceptionally strategic use of cash; *Fair Value Estimate* – our discounted cash flow-derived intrinsic price target.

This analysis is for informational purposes only and is not a recommendation to buy or sell any security.  

### Sources  
1. Humana Inc – “Humana Reports Fourth Quarter 2024 Financial Results; Provides Full Year 2025 Financial Guidance,” Press Release, Feb. 11, 2025 (Humana IR site) ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-Fourth-Quarter-2024-Financial-Results-Provides-Full-Year-2025-Financial-Guidance/default.aspx#:~:text=,to%20Investor%20Relations%20page%20of)).  
2. Humana Inc – “Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance,” Press Release, Apr. 30, 2025 (Humana IR site) ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=,25%27%3B%20while)) ([press.humana.com](https://press.humana.com/news/news-details/2025/Humana-Reports-First-Quarter-2025-Financial-Results-Affirms-Full-Year-2025-Adjusted-Financial-Guidance/default.aspx#:~:text=%27approximately%20%2415.88%27%20,impact%20of%20exiting%20certain%20unprofitable)).  
3. Reuters – “Insurer Humana forecasts annual profit below estimates,” Feb. 11, 2025 (reports 2025 profit ~$16.25 vs $16.71 est.) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-forecasts-annual-profit-lower-than-estimates-2025-02-11/#:~:text=Humana%20has%20projected%20its%202025,per%20share%2C%20matching%20analyst%20estimates)).  
4. Reuters – “Health insurance stocks soar after boost to Medicare reimbursement rates,” Apr. 8, 2025 (5.06% MA payment rate increase to 2026) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/health-insurance-stocks-rise-best-case-scenario-medicare-payment-rates-2025-04-08/#:~:text=Health%20insurance%20stocks%20surged%20following,focused%20Humana%20soared%2016%25%2C%20while)).  
5. Reuters – “Humana shares tumble as 2025 membership for its top-rated Medicare plans slump,” Oct. 2, 2024 (“stock plummeted 15%” on star-rating-driven enrollment drop) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-says-members-its-highly-rated-medicare-advantage-plans-fell-2025-2024-10-02/#:~:text=On%20October%202%2C%202024%2C%20Humana,consumer%20choice%20and%20government%20reimbursements)).  
6. AP News – “Quality ratings hit to key Medicare plan shakes Humana stock,” Oct. 2, 2024 (enrollment in 4-star+ plans down to 25%, ~$1.9B revenue impact estimate) ([apnews.com](https://apnews.com/article/24c77d3535589eb1330777650d9faf3e#:~:text=sharp%20decline%20in%20the%20quality,financial%20performance%20for%202024%20or)).  
7. Reuters – “Humana beats quarterly profit estimates on strength in Medicare business,” Oct. 30, 2024 (3Q24 adj. EPS $4.16 vs $3.40 est.; raised 2024 MA membership growth) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-beats-quarterly-profit-estimates-2024-10-30/#:~:text=Humana%20beat%20Wall%20Street%20expectations,growth%20to%20265%2C000%20from%20225%2C000)).  
8. Reuters – “Humana’s Susan Diamond to step down as CFO in latest management change,” Dec. 3, 2024 (new CFO announced; 2025 adjusted EPS seen ~ $16) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/humana-says-susan-diamond-step-down-cfo-2024-12-03/#:~:text=Humana%20CFO%20Susan%20Diamond%20is,The)).  
9. Reuters – “US accuses health insurers, brokers of Medicare Advantage kickback scheme,” May 1, 2025 (DOJ sues Humana among others for illegal broker kickbacks) ([www.reuters.com](https://www.reuters.com/sustainability/us-files-false-claims-complaint-against-three-health-insurers-2025-05-01/#:~:text=The%20U,their%20agents%20to%20do%20the)).  
10. Axios – “Medicare Advantage’s growth spurt brings tensions,” Oct. 16, 2023 (51% of Medicare beneficiaries on MA plans in 2023) ([www.axios.com](https://www.axios.com/2023/10/16/medicare-advantage-enrollment-growth#:~:text=During%20the%202023%20Medicare%20open,Concerns)).  
11. MacroTrends – “Humana Annual Revenue 2011–2025,” (historical revenues, growth rates for 2022–24) ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/HUM/humana/revenue#:~:text=,increase%20from%202021)).